Senesco Technologies Inc.

ELOX Healthcare Biotechnology

Senesco Technologies Inc.’s revenue for fiscal 2024 (year ended December 2024) was $6.4 million. In the quarter to June 2026, EPS grew 87.7% and free cash flow fell 144.3%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.

13.03 0.67 −4.89%
Market cap
$55.3M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Older periods Jun '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

0.00% 0.00% 78.27% (89.91%)
ROA
(336.49%) 0.00% (141.35%) (34.15%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
0.00% 0.00% 135.09% (25.54%)
Free Cash Flow per Share
(17.32) — (1.83) (1.59)
Free Cash Flow
(6.01) — (8.01) (10.79)
Other line items
Cash ROIC
0.00% 0.00% 659.51% (9.96%)
Accounts Payable Turnover
— 0.00 0.00 0.00
Average Days of Payables
— 0.00 0.00 0.00
Tax Rate
0.00 — 0.00 0.00
Research and Development Expense of Revenue
0.00% — 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
0.00% — 0.00% 0.00%
Share Based Compensation of Revenue
0.00% — 0.00% 0.00%
Operating CF/Net income
0.60 — 0.78 0.91
Depreciation/Fixed assets
0.00 — 0.00 0.00
Capex/Depreciation
0.00 — 0.00 0.00
Revenue per Share
0.00 — 0.00 0.00
Operating CF per Share
(17.32) — (1.83) (1.59)
Capex per Share
0.00 — 0.00 0.00

Fold the line items

Columns are period end dates